Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats by Micheli, Laura et al.
Neuropharmacology and analgesia
Acute and subchronic antinociceptive effects of nociceptin/orphanin
FQ receptor agonists infused by intrathecal route in rats
Laura Micheli a, Lorenzo Di Cesare Mannelli a,n, Remo Guerrini b, Claudio Trapella b,
Matteo Zanardelli a, Roberto Ciccocioppo d, Anna Rizzi c, Carla Ghelardini a, Girolamo Calò c
a Department of Neuroscience, Psychology, Drug Research and Child Health - Neurofarba — Pharmacology and Toxicology Section, University of Florence,
Florence, Italy
b Department of Chemical and Pharmaceutical Sciences and LTTA, University of Ferrara, Ferrara, Italy
c Department of Medical Sciences, Section of Pharmacology and National Institute of Neuroscience, University of Ferrara, Italy
d School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy
a r t i c l e i n f o
Article history:
Received 3 September 2014
Received in revised form
6 February 2015
Accepted 11 February 2015
Available online 19 February 2015
Keywords:
Morphine
Nociceptin/orphanin FQ
NOP receptor agonists
Spinal analgesia
Tolerance
a b s t r a c t
Severe pain occurs in the context of many diseases and conditions and is a leading cause of disability.
Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand of the N/OFQ peptide (NOP) receptor. This
peptidergic system controls pain transmission and in particular spinally administered N/OFQ has robust
antinociceptive properties.
The aim of this study was to investigate the spinal antinociceptive properties of NOP peptide agonists
after acute and subchronic treatment in rats. Doses unable to alter motor coordination were selected.
UFP-112 (full NOP agonist) and UFP-113 (partial NOP agonist) were administered intrathecally (i.t.) by
spinal catheterization. Acute injection of UFP-112 induced antinociceptive response at lower dosages
(0.03–1 nmol i.t.) compared to morphine and similar to N/OFQ. UFP-113 was effective in a 0.001–1 nmol
i.t. dose range. The antinociceptive effects of NOP ligands were no longer evident in rats knockout for the
NOP gene, while those of morphine were maintained. The continuous spinal infusion (by osmotic
pumps) of 0.1 nmol/h UFP-112 and UFP-113 showed antinociceptive action comparable to 1–3 nmol/h
morphine or N/OFQ. The antinociceptive effect of morphine progressively decreased and was no longer
signiﬁcant after 6 days of treatment. Similar results were obtained with N/OFQ, UFP-112, and UFP-113.
The acute i.t. injection of morphine in animals tolerant to N/OFQ and UFP-112 evoked analgesic effects.
Neither morphine nor N/OFQ induced antinociceptive effects in morphine- and UFP-113-tolerant rats. In
conclusion this study highlights the analgesic efﬁcacy and potency of UFP-112 and UFP-113 underlining
the relevance of NOP system in analgesia.
& 2015 Elsevier B.V. All rights reserved.
1. Introduction
Pain represents a widespread public health issue (Goldberg and
McGee, 2011) with several effects on physical, emotional and cogni-
tive functions. In particular, severe pain is deﬁned as pain that persists
beyond normal tissue healing time, or more than 3–6 months
(Verhaak et al., 1998). Its time course is unpredictable and patients
are often difﬁcult to treat (Rowbotham, 1995).
Opioids are the most potent analgesic drugs commonly employed
in order to relief moderate and severe pain (Dahan et al., 2013). Their
effects are mediated by the mu, delta and kappa opioid peptide
receptors (MOP, DOP and KOP, respectively) (Toll et al., 2014; Reisine
and Pasternak, 1996; Waldhoer et al., 2004). Morphine, the gold
standard for relieving pain, binds to all opioid receptors (Kieffer,
1999; Kieffer and Gavériaux-Ruff, 2002; Pasternak, 1993; Reisine and
Bell, 1993) although it displays moderate selectivity for the MOP
receptor (Zadina et al., 1994). Morphine is generally administered
orally, transdermally, subcutaneously or intravenously (Osborne et al.,
1990; Wojciech, 2011) although in the presence of severe pain it may
be infused directly in the neuraxis by intrathecal (i.t.) route (Brogan and
Winter, 2011; Vissers et al., 2011). The i.t. administration of centrally
acting agents bypasses the blood brain barrier resulting in much higher
cerebrospinal ﬂuid concentrations while using reduced amounts of
medication to achieve equieffective doses (Hayek et al., 2011). The
efﬁcacy and safety of this administration route were demonstrated in a
number of studies, supporting its importance for chronic pain states
(Coombs et al., 1984; Duarte et al., 2012; Follett et al., 1992; Krames
et al., 1985, Krames and Lanning, 1993; Onofrio and Yaksh, 1990).
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/ejphar
European Journal of Pharmacology
http://dx.doi.org/10.1016/j.ejphar.2015.02.020
0014-2999/& 2015 Elsevier B.V. All rights reserved.
n Correspondence to: Neurofarba - Pharmacology and Toxicology Section,
University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. Tel.: þ39 055
4271316; fax: þ39 055 4271280.
E-mail address: lorenzo.mannelli@uniﬁ.it (L. Di Cesare Mannelli).
European Journal of Pharmacology 754 (2015) 73–81
Nonetheless, other pharmacological approaches are necessarily
given the complexity of pain mechanisms and the evidence that
chronic pain still represent an unmet medical need. Nociceptin/
orphanin FQ (N/OFQ) acts through the N/OFQ peptide receptor
(NOP) which shares high structural homology with classical opioid
targets (Meunier et al., 1995; Reinscheid et al., 1995). Despite high
structural homology of the receptor and the peptide, and similar
transductional mechanisms the N/OFQ – NOP receptor system is
pharmacologically distinct from classical opioid systems (Lambert,
2008). N/OFQ has been shown to cause hyperalgesia, allodynia or
analgesia depending on the dose and the route of administration.
In most of the studies, N/OFQ supraspinal administration elicits
pronociceptive effects in rodents and is able to counteract the
antinociceptive effects of opioids (Zeilhofer and Calò, 2003). On
the contrary N/OFQ administered i.t. induces antinociceptive
effects (Zeilhofer and Calò, 2003).
The spinal antinociceptive effects of N/OFQ and NOP receptor
agonists have been conﬁrmed in a series of studies in non human
primate (Ko et al., 2006; Ko and Naughton, 2009; Hu et al., 2010).
Intrathecal administration of NOP agonists may represent a new
approach to severe pain treatment. The aim of this study was to
investigate in rats the acute and subchronic spinal effects of N/OFQ
and NOP receptor agonists (UFP-112 and UFP-113) on pain trans-
mission in comparison with the gold standard morphine.
2. Materials and methods
2.1. Animals
Male Sprague–Dawley and Wistar rats were supplied by Harlan
(Varese, Italy). Male NOP(/) rats supplied by GenOway (Lyon,
France) were generated in a Brown Norway background and subse-
quently backcrossed on a Wistar background for eight generations as
previously described in detail (Homberg et al., 2009). For knockout
studies Wistar rats were used as controls and indicated as NOP(þ/þ).
Animals, weighing approximately 280–300 g at the beginning of the
experimental procedure were housed in single cage (size 26
41 cm2). Animals were fed with standard laboratory diet and tap
water ad libitum, and kept at 2371 1C with a 12 h light/dark cycle,
light at 7 a.m. All animal manipulations were carried out according to
the European Community guidelines for animal care (DL 116/92),
application of the European Communities Council Directive of 24
November 1986 (86/609/EEC). The ethical policy of the University of
Florence complies with the Guide for the Care and Use of Laboratory
Animals of the US National Institutes of Health (NIH Publication No.
85-23, revised 1996; University of Florence assurance number: A5278-
01). Formal approval to conduct the experiments described was
obtained from the Animal Subjects Review Board of the University
of Florence and from the Italian Ministry of Health (No 54/2014-B).
Experiments involving animals have been reported according to
ARRIVE guidelines (Kilkenny et al., 2010). All efforts were made to
minimize animal suffering and to reduce the number of animals used.
2.2. Intrathecal catheterization
Rats were anesthetized with 2% isoﬂurane and the intrathecal
catheter was surgically implanted according to (Yaksh and Rudy,
1976). Rats were shaved on the back of the neck and placed in the
stereotaxic frame with the head securely held between ear bars.
The skin over the nap of the neck was cleaned with ethyl alcohol
and incised for 1 cm. The muscle on either side of the external
occipital crest was detached and retracted to expose about
3–4 mm2 of the atlanto-occipital membrane. The membrane was
incised by a needle, which led to the escape of cerebrospinal ﬂuid.
The caudal edge of the cut was lifted and about 7.0 cm of 28 G
polyurethane catheter (0.36 mm outer diameter; 0.18 mm inner
diameter; Alzet, USA) was gently inserted into the intrathecal
space in the midline, dorsal to the spinal cord until the lumbar
enlargement. The exit end of the catheter was connected to 4.0 cm
polyurethane (0.84 mm outer diameter; 0.36 mm inner diameter)
and was taken out through the skin, ﬂushed with saline solution,
sealed and securely ﬁxed on the back of the head with a silk
suture. For the chronic treatments osmotic pumps (Alzet, USA)
were used. Pumps were attached with the exit end of the catheter
and subcutaneously ﬁxed on the back of the head. The incision site
in the skin was sutured with polyamide suture and animals were
allowed to recover for 24 h before the study began.
All animals used during behavioral tests did not shown motor
impairment induced by surgical operation for the catheter implan-
tation. The evaluation of potential motor dysfunctions were
investigated using Rota rod test. The animals displaying motor
disabilities (approximately 10%) were excluded from the beha-
vioral measurements.
2.3. Drug treatments
Morphine hydrochloride was from S.A.L.A.R.S., Como, Italy.
N/OFQ, UFP-112 ([(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2), and UFP-
113 ([Phe1Ψ(CH2-NH)Gly2(pF)Phe4 Aib7Arg14Lys15]N/OFQ-NH2)
were synthesized and puriﬁed as previously described in detail
(Arduin et al., 2007; Guerrini et al., 1997). All compounds were
dissolved in sterile saline solution. Acute measures were per-
formed after the i.t. infusion of 0.1–3 nmol morphine, 0.01–3 nmol
N/OFQ, 0.03–0.3 nmol UFP-112 and 0.001–1 nmol UFP-113. All
Fig. 1. A) Effect induced by intrathecal administration of morphine (dissolved in
sterile saline) at doses from 0.1 to 3 nmol i.t. Analgesic effect was evaluated by Paw-
pressure test performing from 15 to 180 min after acute injection. B) The Area
Under Curve (AUC) represents the antinociceptive effect induced by acute intrathe-
cal administration of morphine (0.1–3 nmol) between 0 and 120 min. Each value
represent the mean of 6 rats performed in 2 different experimental set. Data are
shown as mean7S.E.M.; *Po0.05 and **Po0.01 in comparison to saline treated
animals.
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compounds were infused in a ﬁnal volume of 10 ml. Behavioral
tests were carried out after 15, 30, 45, 60, 90, 120 and 180 min.
For subchronic treatments, compound concentrations were
adjusted to release 1 and 3 nmol/h morphine or N/OFQ, and
0.1 nmol/h UFP-112 or UFP-113, from a mini-osmotic pump ALZET
1002 (USA) with a ﬂow rate 0.25 mL/h for 14 days. Final solutions
were ﬁltered by a 0.22 mm pore size Hydrophilic PVDF membrane
(Millipore, Italy). Mini-pump were attached to the described
polyurethane catheters and ﬁlled with compounds or vehicle
solutions, respectively. All mini-osmotic pumps were incubated
in sterile saline solution overnight at 37 1C.
2.4. Paw pressure test
The nociceptive threshold in the rat was determined with an
analgesimeter (Ugo Basile, Varese, Italy), according to the method
described by (Leighton et al., 1988). Brieﬂy, a constantly increasing
pressure was applied to a small area of the dorsal surface of the
paw using a blunt conical probe by a mechanical device. Mechan-
ical pressure was increased until vocalization or a withdrawal
reﬂex occurred while rats were lightly restrained. Vocalization or
withdrawal reﬂex thresholds were expressed in grams; a cut off
pressure of 200 g was used to avoid tissue damage. All experi-
ments were performed by a researcher blind to drug treatment.
2.5. Rota-rod test
Rota-rod apparatus (Ugo Basile, Varese, Italy) consisted of a base
platform and a rotating rod with a diameter of 6 cm and a non-
slippery surface. The rod was placed at a height of 25 cm from the
base. The rod, 36 cm in length, was divided into 4 equal sections
Table 1
Evaluation of motor coordination after acute intrathecal administration of morphine, N/OFQ, UFP-112 and UFP-113.
Number of falls
Pretest 15 min 30 min 45 min 60 min 90 min 120 min
Saline 1.070.5 0.070.0 1.070.2 0.070.4 0.070.0 0.070.0 0.070.0
Morphine 3 nmol 0.570.5 0.070.0 0.070.0 0.370.2 0.070.0 0.070.0 0.070.0
N/OFQ 3 nmol 1.070.2 0.070.0 0.570.5 0.370.0 0.070.0 1.070.0 0.070.0
UFP-112 0.3 nmol 1.070.5 1.070.6 0.070.0 0.570.5 0.070.0 0.070.0 0.570.3
UFP-113 1 nmol 0.070.0 0.070.0 0.070.0 0.070.0 0.070.0 0.070.0 0.070.0
Rota rod was performed recording the number of falls from the rod during 60 s. Measurements were repeated over time after intrathecal treatments. Each value represent
the mean of 6 rats performed in 2 different experimental set. Data are shown as mean7s.e.m.
Fig. 2. A) Effect induced by intrathecal administration of N/OFQ (dissolved in
sterile saline) at doses from 0.01 to 3 nmol i.t. Analgesic effect was evaluated by
Paw-pressure test performing from 15 to 180 min after acute injection. B) The Area
Under Curve (AUC) represents the antinociceptive effect induced by acute intrathe-
cal administration of N/OFQ (0.01–3 nmol) between 0 and 120 min. Each value
represent the mean of 6 rats performed in 2 different experimental set. Data are
shown as mean7S.E.M.; *Po0.05 and **Po0.01 in comparison to saline treated
animals.
Fig. 3. A) Effect induced by intrathecal administration of UFP-112 (dissolved in
sterile saline) at doses from 0.03 to 0.3 nmol i.t. Analgesic effect was evaluated by
Paw-pressure test performing from 15 to 180 min after acute injection. B) The Area
Under Curve (AUC) represents the antinociceptive effect induced by acute intrathe-
cal administration of UFP-112 (0.03–0.3 nmol) between 0 and 120 min. Each value
represent the mean of 6 rats performed in 2 different experimental set. Data are
shown as mean7S.E.M.; *Po0.05 and **Po0.01 in comparison to saline treated
animals.
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by 5 disks. Thus, up to 4 rats were tested simultaneously on the
apparatus, with a rod-rotating speed of 10 rpm. The integrity of motor
coordinationwas assessed on the basis of the number of falls from the
rod in 60 s measured after 15, 30, 45, 60, 90 and 120min after
treatment for acute protocol. For subchronic treatments measure-
ments were performed daily for 120 s. A cut off of 6 falls was used.
2.6. Statistic analysis
Behavioral measurements were performed on 6 rats for each
treatment carried out in 2 different experimental sets. Results
were expressed as means7S.E.M. and the analysis of variance was
performed by one way ANOVA. A Bonferroni's signiﬁcant differ-
ence procedure was used as post-hoc comparison. P values of less
than 0.05 or 0.01 were considered signiﬁcant. Data were analyzed
using the “Origin 9” software. Behavioral results of NOP(þ/þ) vs
NOP(/) were analyzed by two way ANOVA followed by a
Tukey's post-hoc test (“GraphPad Prism 6” software). The area
under the curve (AUC) of the antinociceptive effects was calculated
using the “Origin 9” software, evaluating the data from 0–120 min.
3. Results
3.1. Acute antinociceptive effects
The analgesic effects of acute i.t. injections of morphine and NOP
agonists were evaluated in the rat paw pressure test. Animals
injected with saline displayed a nociceptive threshold around 60 g
that was stable over the time course of the experiments. Increasing
doses of i.t. morphine (0.1–3 nmol) evoked a robust antinociceptive
effect in a dose-dependent manner (Fig. 1, panel A). The peak effect
was measured after 30 min from injection for all doses. The maximal
effect corresponding to 140.075.0 g was obtained in response to
3 nmol morphine and the antinociceptive action of this dose was
signiﬁcant until 90 min and vanished 120 min after administration.
The dose response curve to i.t. morphine expressed as area under the
curve is shown in the panel B of Fig. 1. In this dose range morphine
did not modify animal performance in the rota-rod test (Table 1).
Likewise morphine, 0.01–3 nmol N/OFQ was tested i.t. to
evaluate its analgesic effect in the rat (Fig. 2, panel A). All N/OFQ
doses evoked antinociceptive effects starting 15 min after admin-
istration and peaked at 30–45 min after injection. 3 mnol i.t.
N/OFQ showed the highest antinociceptive effect that lasted up
to 120 min. The dose response curve of i.t. N/OFQ expressed as
area under the curve is shown in the panel B of Fig. 2. At all dose
tested N/OFQ did not led to any motor impairment in the rat rota-
rod test (Table 1). However at higher doses (i.e. 10 nmol i.t.) N/OFQ
caused a clear impairment of animal motor performance.
Fig. 3 panel A shows the antinociceptive effect of acute intrathecal
administration of the NOP selective full agonist UFP-112 tested in a
dose range from 0.03 to 0.3 nmol. The antinociceptive effect induced
by this NOP agonist was dose-dependent. At 0.3 nmol i.t. the com-
pound evoked the maximal effect at 30 min after intrathecal injection,
the weight tolerated on the posterior paw was of 114.873.0 g (in
comparison to basal value 58.370.8 g). The effect was signiﬁcant until
120 min after administration. The dose response curve of i.t. UFP-112
expressed as area under the curve is shown in the panel B of Fig. 3. At
higher doses (1 and 3 nmol), UFP-112 caused an impairment of motor
coordination up to the paralysis of posterior paws (10 nmol).
Acute effects of the NOP partial agonist UFP-113 were evaluated
after the administration of doses ranging 0.001 and 1 nmol i.t. (Fig. 4,
panel A). Similar to UFP-112, the dose of 3 nmol and 10 nmol impeded
the maintenance of balance on the rotating rod or paralyzed posterior
paws, respectively. Lower doses of UFP-113 did not evoked motor side
effects in the rat. The analgesic response to 1 nmol i.t. of UFP-113
appeared 15min after injection (83.373.5 g) with a maximum
response around 30min (103.879.6 g). The effect progressively
decreased over time, vanishing 120min after administration
(55.374.8 g). At doses between 0.03–0.3 UFP-113 led to time-
dependent and dose-dependent antinociceptive effects. Analgesia
started 15min after injection and reached the maximum values
between 30 and 45min. The dose of 0.3 nmol i.t. induced the highest
antinociceptive effect that was reached 45min after compound
administration (101.772.6 g). The dose response curve of i.t.
UFP-113 expressed as area under the curve is shown in the panel B
of Fig. 4. The spinal antinociceptive effects of these compounds were
also assessed in NOP(/) rats. Results obtained with 3 nmol
morphine and N/OFQ, 0.3 nmol UFP-112 and 1 nmol UFP-113 were
summarized in Fig. 5. Pain threshold were similar in NOP(þ/þ) and
NOP(/) rats. Morphine elicited a robust antinociceptive effect in
both NOP(þ/þ) and NOP(/) animals (Fig. 5A); however the effect
of the alkaloid was larger in NOP(þ/þ) rats The AUC were also
calculated in Wistar NOP(þ/þ) and NOP(/) rats and two way
ANOVA was performed. The AUC of 3 nmol morphine antinociceptive
effect in NOP(þ/þ) rats was statistically different in comparison to
the AUC of 3 nmol morphine in NOP(/) rats (13640.627178.12
and 10182.56749.07, respectively; Po0.001). In NOP(þ/þ) rats,
N/OFQ, UFP-112, and UFP-113 displayed antinociceptive effects similar
to those obtained in SD animals while their effect completely
disappeared in NOP(/) animals (Fig. 5 panel B, C, and D).
3.2. Subchronic antinociceptive effects
We used the same surgical procedure of spinal catheterization
to analyze the analgesic proﬁle of these compounds during a
continuous i.t. infusion. To allow a constant delivery of substances
Fig. 4. A) Effect induced by intrathecal administration of UFP-113 (dissolved in sterile
saline) at doses from 0.001 to 1 nmol i.t. Analgesic effect was evaluated by Paw-pressure
test performing from 15 to 180 min after acute injection. B) The Area Under Curve (AUC)
represents the antinociceptive effect induced by acute intrathecal administration of UFP-
113 (0.001–1 nmol) between 0 and 120min. Each value represent the mean of 6 rats
performed in 2 different experimental set. Data are shown as mean7S.E.M.; *Po0.05
and **Po0.01 in comparison to saline treated animals.
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over days, mini-osmotic pumps connected to the catheters were
used. Pain threshold and motor coordination were evaluated every
day by paw pressure and rota rod tests.
Morphine was continuously infused into two different groups of
animals at the doses of 1 and 3 nmol/h (Fig. 6). Every day the
analgesic effect was measured in comparison with rats treated with
saline solution by the same route of administration. Animal treated
with saline displayed stable pain threshold over the time course of
the experiment (8 days). The ﬁrst day of infusion the nociceptive
threshold reached 118.579.0 g and 126.677.6 g for 1 and 3 nmol/
h-treatment group, respectively. Antinociceptive effect started to
decrease from day 2 until day 5 of infusion when the values
recorded were still statistically signiﬁcant (72.174.6 g for 1 nmol/
and 75.077.4 g for 3 nmol/h). Starting from day 6 no differences
were evident in pain threshold of animal treated with spinal
morphine or saline (Fig. 6). Similar to morphine, N/OFQ was
continuously infused spinally at doses of 1 and 3 nmol/h. (Fig. 7).
Both doses induced a robust antinociceptive effect that peaked the
ﬁrst day of infusion (112.574.6 g for 1 nmol/h and 127.574.9 g for
3 nmol/h), and then progressively decreased over the time course of
Fig. 5. A) Effect induced by intrathecal administration of morphine 3 nmol (dissolved in sterile saline) in NOP(þ/þ) and NOP(/) rats. Analgesic effect was evaluated by
Paw-pressure test from 15 to 180 min after acute injection. B) Effect induced by intrathecal administration of N/OFQ 3 nmol (dissolved in sterile saline) in NOP(þ/þ) and
NOP(/) rats. Analgesic effect was evaluated by the Paw-pressure test from 15 to 180 min after acute injection. C) Effect induced by intrathecal administration of UFP-112
0.3 nmol (dissolved in sterile saline) in NOP(þ/þ) and NOP(/) rats. Analgesic effect was evaluated by Paw-pressure test from 15 to 180 min after acute injection. D) Effect
induced by intrathecal administration of UFP-113 1 nmol (dissolved in sterile saline) in NOP(þ/þ) and NOP(/) rats. Analgesic effect was evaluated by Paw-pressure test
from 15 to 180 min after acute injection. Each value represent the mean of 6 rats performed in 2 different experimental set. Data are shown as mean7S.E.M.; *Po0.05 and
**Po0.01 in comparison to saline treated animals.
Fig. 6. Effect induced by continuous intrathecal infusion of morphine. The
compound was dissolved in sterile saline and administered in two different groups
of animals at doses of 1 and 3 nmol/h with osmotic pumps until day 8. Analgesic
effect was evaluated every day by Paw-pressure test during the entire duration of
treatment, starting on the 1th day of infusion. Each value represents the mean of
6 rats performed in 2 different experimental set. Data are shown as mean7S.E.M.;
**Po0.01 in comparison to control animals treated with saline.
Fig. 7. Effect induced by continuous intrathecal infusion of N/OFQ. The compound
was dissolved in sterile saline and administered in two different groups of animals
at doses of 1 and 3 nmol/h with osmotic pumps until day 8. Analgesic effect was
evaluated every day by Paw-pressure test during the entire duration of treatment,
starting on the 1th day of infusion. Each value represent the mean of 6 rats
performed in 2 different experimental set. Data are shown as mean7S.E.M.;
*Po0.05 and **Po0.01 in comparison to control animals treated with saline.
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the experiment. On day 8 no differences were evident in pain
threshold of animal treated with spinal N/OFQ or saline (Fig. 7).
Fig. 8 displays the antinociceptive effect of UFP-112 and UFP-113,
both given as continuous i.t. infusion at the dose of 0.1 nmol/h. On day
1, UFP-112 increased pain threshold up to 101.077.8 g in comparison to
pain threshold measured in saline-treated animals (71.773.9). The
antinociceptive effect of UFP-112 was statistically signiﬁcant up to day 5.
Animals continuously infused with UFP-113 showed a pain threshold of
93.773.5 g on the ﬁrst day of treatment. The effect of UFP-113 was
statistically signiﬁcant up to day 7. During compound infusion, the
motor coordination of the animals was evaluated every day by the rota
rod test (Table 2). Motor coordination of morphine, N/OFQ, UFP-112 and
UFP-113 treated animals, evaluated as number of falls during 120 s, did
not show signiﬁcant differences compared to saline-infused animals.
Finally at day 9 osmotic pumps were removed to evaluate the
effect of acute treatment with 3 nmol of N/OFQ and morphine in
tolerant animals.
In spinal morphine tolerant animals the acute i.t. administration
of 3 nmol of morphine or N/OFQ did not modify pain threshold
(Fig. 9A). The same experiments were performed in spinal N/OFQ
tolerant rats (Fig. 9B). Acute intrathecal administration of morphine
induced a clear antinociceptive effect 15 and 30 min after injection
with a weight of 96.273.3 and 92.774.6 respectively. In these
animals the spinal injection of N/OFQ was inactive. Similar results
were obtained in spinal UFP-112 tolerant rats in which acute
morphine produced statistically signiﬁcant effects while N/OFQ was
inactive (Fig. 9C). In animals tolerant to the spinal effects of UFP-113
both morphine and N/OFQ were inactive (Fig. 9D).
4. Discussion
In spite of opioid efﬁcacy (Pasternak and Pan, 2013) an estimated
80% of persons worldwide do not receive adequate treatment to
relieve pain (WHO, 2007). The unsuitableness of therapy is often
related to legal restrictions on the availability of opioid analgesics
(Weber et al., 2012), furthermore adverse effects limit the use of these
drugs (Morgan,1989). Along with increase in the prevalence of chronic
pain, long-term therapies with opioids exacerbate toxicity and the
development of analgesic tolerance (Williams et al., 2013) and
dependence is a signiﬁcant limit in their clinical applications (Koob
and Bloom,1988). Research efforts in the ﬁeld of analgesics are focused
on the discovery of new compounds as well as of new pharmaceutical
forms and routes of administration. The i.t. route offers a safe and
effective alternative when i.v. or oral opioids are only partially effective
(Grady and Raphael, 2008; Grider et al., 2011) e.g. for the management
of chronic non-cancer pain (Biggs et al., 2011; De Lissovoy et al., 1997;
Hassenbusch et al., 1997). Recent studies support the long-term
effectiveness following 3 years of treatment (Duarte et al., 2012).
Opioid administration into the intrathecal space achieves its effects at
lower doses than by using the epidural route (Nordberg et al., 1984).
The drug is highly localized, and its analgesic efﬁcacy is maximized at
lower doses (Bernards, 2006) reducing systemic narcotic exposure by a
factor of 300 to 1 (Smith et al., 2005). Moreover, opioid dose escalation
over time may be modest. These factors lead to a decrease in the
appearance of opioid side effects (Duarte et al., 2012).
Aimed to reach an alternative and exploitable pharmacological
target by spinal delivery, we compared the efﬁcacy of morphine with
that of NOP receptor agonists. Spinal morphine produced a dose
dependent and robust antinociceptive effect in line with previous
ﬁndings (Kosson et al., 2008). A similar antinociceptive action has been
promoted by the spinal injection of N/OFQ accordingly to (Schroder
et al., 2014; Zeilhofer and Calò, 2003;). Compared to morphine, N/OFQ
displayed similar potency but reduced maximal effects. This is possibly
due to the appearance of side effects for the high doses of peptide
(ﬂaccidity of the hindlimbs and consequent disruption of rota-rod
performance). Similar ﬁndings were reported in mice (Nazzaro et al.,
2007). Thus, in rodents the therapeutic index of N/OFQ as spinal
analgesic is clearly lower than that of morphine. However different
results were obtained in non human primates where the i.t. admin-
istration of N/OFQ in a large range of doses produced robust
antinociceptive effects without affecting motor behavior (Hu et al.,
2010; Ko and Naughton, 2009). Importantly, the antinociceptive
maximal effects of N/OFQ were similar to that of morphine. Moreover
the action of N/OFQ was behaviorally selective; in fact the adminis-
tration of analgesic doses of morphine promoted scratching responses
in monkeys while N/OFQ did not. This evidence suggests the existence
of relevant species differences regarding the therapeutic potential of
NOP agonists as spinal analgesics (Schroder et al., 2014).
UFP-112 is a NOP receptor ligand designed by combining several
chemical modiﬁcations in the same peptide sequence to increase NOP
receptor afﬁnity/potency and/or reduce susceptibility to enzymatic
degradation (Rizzi et al., 2007). The NOP receptor full agonist
pharmacological activity of UFP-112 has been conﬁrmed in several
in vitro and in vivo studies reviewed in Calo' et al. (2011). In the
present study, UFP-112 elicited a dose-dependent antinociceptive
response after acute i.t. administration in the rat showing similar
efﬁcacy and potency as N/OFQ. Similar although not superimposable
results were previously obtained in mice (Rizzi et al., 2011) where
UFP-112 was 100 fold more potent that N/OFQ and produced longer
lasting effects. The spinal antinociceptive properties of UFP-112 were
also conﬁrmed in monkeys (Hu et al., 2010). Collectively this evidence
demonstrated that UFP-112 mimicked the antinociceptive effects of
N/OFQ in the rat, mouse and monkeys showing similar or higher
potency than the natural peptide.
The spinal antinociceptive action of the NOP partial agonist UFP-
113 (Arduin et al., 2007; Camarda et al., 2009) has been evaluated in
the present research for the ﬁrst time. Acute i.t. administration of
UFP-113 increased pain threshold in a dose dependent manner and
with high potency. Despite the NOP partial agonist activity measured
in in vitro studies (Arduin et al., 2007) with this molecule, UFP-113
maximal antinociceptive effects were similar to those measured in
response to spinal N/OFQ and UFP-112. This result is not completely
unexpected. In fact, the NOP partial agonist [F/G]N/OFQ(1–13)–NH2
that shares with UFP-113 the chemical modiﬁcation at the Phe1-Gly2
peptide bond that reduces efﬁcacy (Calo' et al., 2000) displayed full
agonist activity when given spinally in the rat tail ﬂick test
(Candeletti et al., 2000, Wang et al., 1999).
Doses higher than 0.3 nmol for UFP-112 and 1 nmol for UFP-113
induced disruption of motor coordination. This side effect is also
evoked by N/OFQ at high doses (i.e. 10 nmol). This order of potency
Fig. 8. Effect induced by continuous intrathecal infusion of UFP-112 and UFP-113.
Compounds were dissolved in sterile saline and administered in two different
groups of animals both at dose of 0.1 nmol/h with osmotic pumps until day 8.
Analgesic effect was evaluated every day by Paw-pressure test during the entire
duration of treatment, starting on the 1th day of infusion. Each value represent the
mean of 6 rats performed in 2 different experimental set. Data are shown as
mean7S.E.M.; *Po0.05 and **Po0.01 in comparison to control animals treated
with saline.
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perfectly matches the rank order of potency of these peptides as NOP
ligands (Arduin et al., 2007) thus suggesting that motor impairment
derives from an overstimulation of spinal NOP receptors.
NOP(/) rats (Homberg et al., 2009) were used to investigate
the involvement of the NOP receptor in the antinociceptive action
of the compounds under study. NOP(þ/þ) and NOP(/) rats
displayed similar pain threshold in the Paw pressure test. This is in
line with studies performed in NOP knockout mice (Depner et al.,
2003; Nishi et al., 1997) suggesting that the endogenous N/OFQ –
NOP receptor system does not tonically control nociceptive trans-
mission (Zeilhofer and Calò, 2003). The spinal injection of mor-
phine in NOP(/) rats produced a clear antinociceptive effect
while N/OFQ, UFP-112 and UFP-113 were completely inactive.
These ﬁndings clearly demonstrated the exclusive involvement
of the NOP receptor in the spinal antinociceptive action of these
latter compounds. Interestingly the antinociceptive effect of mor-
phine was reduced in NOP(/) compared to NOP(þ/þ) rats.
This ﬁnding contrasts with that reported in mice where the
analgesic effect of morphine was similar in NOP(þ/þ) and NOP
(/) animals (Mamiya et al., 2001; Ueda et al., 1997). This might
suggest an involvement of N/OFQergic signaling in the antinoci-
ceptive action of spinal morphine in rats but not in mice.
Results obtained in acute dose response studies were used to
select the appropriate doses of compounds to be assessed for their
effects during continuous infusion. All compounds did not induce
motor dysfunctions during infusion at the described dosages. Mor-
phine induces signiﬁcant analgesic effect that displayed progressive
reduction over the time course of the experiment. After 6 days of
Table 2
Evaluation of motor coordination during continuous intrathecal infusion of morphine, N/OFQ, UFP-112 and UFP-113.
Number of falls
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Saline 1.170.5 1.070.2 1.170.3 1.370.4 1.070.1 0.570.2 0.770.3
Morphine 3 nmol 1.570.2 0.570.2 0.570.2 1.070.0 0.570.3 0.070.0 0.070.0
N/OFQ 3 nmol 0.370.3 1.370.8 1.170.5 0.370.0 0.070.0 1.070.0 0.070.0
UFP-112 0.1 nmol 1.570.7 1.271.3 1.570.8 1.270.8 1.071.0 1.070.3 0.070.0
UFP-113 0.1 nmol 1.270.8 1.470.5 1.070.8 1.070.4 0.070.0 0.570.5 1.070.1
Rota rod was performed recording the number of falls from the rod during 120 s. Measurements were repeated every day during subchronic treatment. Each value represent
the mean of 6 rats performed in 2 different experimental sets. Data are shown as mean7s.e.m.
Fig. 9. Cross tolerance evaluation after continuous intrathecal infusion of morphine, N/OFQ, UFP-112 and UFP-113 in four different groups of rats. A) Acute intrathecal
administration of morphine and N/OFQ in animals morphine tolerant (after 8 days of morphine 3 nmol/h continuous intrathecal infusion). Analgesic effect was evaluated by
Paw pressure test from 15 to 60 min after administration. B) Acute intrathecal administration of morphine and nociceptin in animals nociceptin tolerant (after 8 days of
N/OFQ 3 nmol/h continuous intrathecal infusion). Analgesic effect was evaluated by Paw pressure test from 15 to 60 min after administration. C) Acute intrathecal
administration of morphine and N/OFQ in animals UFP-112 tolerant (after 8 days of UFP-112 0.1 nmol/h continuous intrathecal infusion). Analgesic effect was evaluated by
Paw pressure test from 15 to 60 min after administration. D) Acute intrathecal administration of morphine and N/OFQ in animals UFP-113 tolerant (after 8 days of UFP-113
0.1 nmol/h continuous intrathecal infusion). Analgesic effect was evaluated by Paw pressure test from 15 to 60 min after administration. Each value represents the mean of
6 rats. Data are shown as mean7S.E.M.; **Po0.01 in comparison to the pretest.
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continuous infusion rats become fully tolerant to the antinociceptive
effect of the alkaloid according to previous studies (Huang et al.,
2012; Jhamandas et al., 1998; Wen et al., 2005). Similar results, acco-
rdingly with (Hao et al., 1997; Jhamandas et al., 1998), were obtained
in rats treated with N/OFQ that become fully tolerant to the action of
the peptide after 8 days. Rats treated with continuous infusion of
UFP-112 or UFP-113 also display a progressive reduction of their
antinociceptive effects and become fully tolerant after 6 and 8 days
respectively. The partial agonist proﬁle of UFP-113 does not seem to
be sufﬁcient to signiﬁcantly affect the development of tolerance.
In order to get information about cross tolerance between NOP
and classical opioid receptors, at day 9 tolerant rats were acutely
injected with 3 nmol of N/OFQ or morphine. In rats tolerant to N/OFQ
or UFP-112, the injection of morphine elicited a signiﬁcant antinoci-
ceptive effect; compared to naïve animals however morphine efﬁcacy
was reduced. These results are at least partially in line with what
reported by (Hao et al., 1997) who demonstrated in the rat tail ﬂick
assay a complete lack of cross tolerance to morphine in N/OFQ-
tolerant rats. The alkaloid was completely inactive in rats tolerant to
UFP-113. This result suggests that classical opioid receptors might be
involved into the antinociceptive action of this compound despite the
high NOP selectivity of UFP-113 reported in receptor binding studies
(Arduin et al., 2007) and conﬁrmed by the present acute studies in
NOP(/) rats. However we cannot completely exclude the involve-
ment of classical opioid receptors in the subchronic action of UFP-113.
In fact, some effects of the UFP-113 analog [F/G]N/OFQ(1–13)–NH2 are
partially reversed by naloxone (Carpenter and Dickenson, 1998).
20Finally the i.t. injection of N/OFQ was inactive in morphine
tolerant rats. This result is in line with the ﬁndings of Jhamandas
et al. (1998) who demonstrated that the dose response curve to
N/OFQ is signiﬁcantly shifted to the right in morphine-tolerant rats.
However other studies demonstrated lack of tolerance to the anti-
nociceptive effects of N/OFQ in morphine tolerant rats (Hao et al.,
1997). Thus the appearance (or lack) of cross tolerance between the
spinal antinociceptive effect of N/OFQ and classical opioids seems to
strongly depend on experimental conditions in rodents.
5. Conclusion
Intrathecal administration of N/OFQ, the NOP full agonist UFP-
112 and the partial agonist UFP-113 produced a dose dependent
antinociceptive effect with the following rank order of potency
UFP-1134UFP-112ZN/OFQ. The exclusive involvement of the
NOP receptor in the antinociceptive action of these compounds
has been conﬁrmed by knockout studies. Compared to morphine,
the spinal antinociceptive potential of NOP agonist is limited by
the appearance of motor side effects. Chronic studies demon-
strated a similar tolerance liability for morphine and NOP agonists.
Cross tolerance studies suggest a higher impact for morphine
continuous infusion on N/OFQ induced antinociception then vice
versa. This study extended our knowledge on the potential of NOP
agonists as spinal analgesics. Importantly this information can be
in instrumental for the design of proof of concept studies in non
human primates where the potential of NOP agonists as analgesics
seems to be extremely promising (Lin and Ko, 2013). However ﬁrm
conclusions on the therapeutic potential of NOP agonists as
innovative spinal analgesics can be drawn only after performing
clinical trials in which N/OFQ will be spinally administered in pain
patients (Al Hashimi et al., 2012).
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